Criptine 2.5 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Bromocriptine mesylate |
| Company | Renata limited |
Title
Bromocriptine Mesilate Tablets
Categories
- Medicine
- Pharmaceutical
Description
Bromocriptine Mesilate Tablets are indicated for hyperprolactinemia-associated dysfunctions, prolactin secreting adenomas, acromegaly, and Parkinson's disease. It is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in humans and is available in tablet form for oral administration.
Formulation
Tablets
DosageStrength
0.5 mg, 2.5 mg
ColorOptions
- White
Indications
- Hyperprolactinemia-Associated Dysfunctions
- Prolactin secreting adenomas
- Acromegaly
- Parkinson's Disease
Pharmacology
Bromocriptine mesilate is a dopamine receptor agonist that significantly reduces plasma levels of prolactin in patients with physiologically elevated prolactin as well as in patients with hyperprolactinemia.
DosageAndAdministration
- General: It is recommended to be taken with food. Patients should be evaluated frequently during dose escalation.
- HyperprolactinemicIndications: Initial dosage is 0.5 mg to 2.5 mg tablet daily with further dose adjustments.
- Acromegaly: Initial recommended dosage is 0.5 to 2.5 mg on retiring (with food) for 3 days with further dose adjustments.
- ParkinsonsDisease: Initiate treatment at a low dosage and then adjust based on patient response.
Interactions
- DopamineAntagonists: May interact with dopamine antagonists.
- ErgotAlkaloids: Concomitant use with other ergot alkaloids is not recommended.
Contraindications
- Uncontrolled hypertension
- Sensitivity to ergot alkaloids
- Postpartum period in women with severe cardiovascular conditions
SideEffects
- Nausea
- Headache
- Dizziness
- Fatigue
- Vomiting
- Abdominal cramps
- Nasal congestion
- Constipation
- Diarrhea
- Drowsiness
PregnancyAndLactation
Pregnancy category B. Should not be used during lactation in postpartum women.
PrecautionsAndWarnings
- RenalOrHepaticDisease: Safety and efficacy have not been established in patients with renal or hepatic disease.
- BloodPressureMedication: Exercised caution when administering concomitantly with other medications known to lower blood pressure.
- PsychosisOrCardiovascularDisease: Use with caution in patients with a history of psychosis or cardiovascular disease.
- Pregnancy: Cautious observation required if used during pregnancy.
PediatricUses
No data are available for bromocriptine use in pediatric patients under the age of 8 years.
TherapeuticClass
- Antiparkinson drugs
- Motility stimulants/Dopamine antagonist
StorageConditions
Keep below 30°C temperature, away from light and moisture. Keep out of the reach of children.